The drug works by removing accumulated amyloid beta proteins in the brain, slowing the progress of the disease. Those ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Healthy obesity is defined as having a BMI of 25 kg/m² or higher without metabolic diseases or with only one metabolic ...

The availability of amyloid-reducing therapies now makes detection of Alzheimer's disease in its early stages critical, ...

NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the ...

Analyst Jason Butler of JMP Securities reiterated a Buy rating on Prothena (PRTA – Research Report), retaining the price target of ...

In recent years, the focus of clinical development has been on immunotherapeutic compounds aimed at clearing brain ...

Nov. 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic ...

In a major discovery, scientists have presented the first evidence of Alzheimer's disease transmission in living individuals.

Deep sleep could be key to forestalling slow declines in brain health that may one day lead to Alzheimer's disease, the most common form of dementia.

Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.

single-injection once-monthly antibody delivered subcutaneously for the treatment of Alzheimer's disease that targets a key epitope at the N-terminus of amyloid beta (Aß) with high binding potency.